Adeola Olaitan

Dr. Adeola Olaitan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
SBStacey Bryan
Stacey Bryan
CBCynthia Barbara
Cynthia Barbara
JTJane Thomas
Jane Thomas
AOAdeola Olaitan
Adeola Olaitan
HPV DNA is found in almost 80% of VIN/VaIN. Current management is inadequate, with high recurrence rates. Our objective was to review the literature regarding the role of HPV vaccine in secondary prevention and treatment of VIN/VaIN. Database searches included Ovid Medline, Embase, Web of Science, The Cochrane Library and Clinicaltrials.gov . Search terms included HPV vaccine AND therapeutic vaccine* AND VIN OR VAIN, published in English with no defined date limit. Searches were carried out with a UCL librarian in March 2018. We included any type of study design using any form of HPV vaccine in the treatment of women with a histologically confirmed diagnosis of VIN/VaIN. We excluded studies of other lower genital tract disease, vulval/vaginal carcinoma and prophylactic use of vaccines. The outcome measures were lesion response to vaccination, symptom improvement, immune response and HPV clearance. We identified 93 articles, 7 studies met our inclusion criteria; these were uncontrolled case series. There were no RCTs or systematic reviews identified. Reduction in lesion size was reported by all 7 studies, symptom relief by 5, HPV clearance by 6, histological regression by 5, and immune response by 6. This review finds the evidence relating to the use of HPV vaccine in the treatment of women with VIN/VaIN is of very low quality and insufficient to guide practice. Further longitudinal studies are needed to assess its use in prevention of progression to cancer.

14 February 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
OIOjone Illah
Ojone Illah
DADeborah Adeeko
Deborah Adeeko
AOAdeola Olaitan
Adeola Olaitan
AGAleksandra Gentry-Maharaj
Aleksandra Gentry-Maharaj
Black women are twice as likely to die from endometrial cancer (EC) compared with white women. This represents one of the worst racioethnic disparities amongst all cancers globally. Compared with white women, black women are more likely to be diagnosed with advanced EC, have more barriers to accessing care and experience increased delays in obtaining an EC diagnosis and commencing treatment. Histological and molecular differences place black women at higher risk of being diagnosed with more aggressive EC subtypes that carry less favourable outcomes. Furthermore, EC diagnostic pathways are less reliable in black women, and black women are less likely to receive evidence-based treatment for EC. This racioethnic disparity in EC outcomes exists both in the UK and US, despite differences in healthcare systems. This review methodically describes the key factors along the patient journey that contribute to the disparity in black women and proposes multifaceted approaches to lessen these gaps.

6 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MGMichelle Gomes
Michelle Gomes
EPElena Provaggi
Elena Provaggi
APANDREA BARNABAS PEMBE
ANDREA BARNABAS PEMBE
AOAdeola Olaitan
Adeola Olaitan
AGAleksandra Gentry-Maharaj
Aleksandra Gentry-Maharaj
Cervical cancer causes 350,000 deaths annually, with 90% occurring in low- and middle-income countries (LMICs), despite being largely preventable through vaccination and screening. This review examines innovative approaches to address screening coverage gaps worldwide, analysing both established programmes in high-income countries and implementation strategies for LMICs. Self-sampling technologies demonstrate significant potential to improve the uptake of cervical screening, thereby improving cervical cancer prevention compared to traditional methods, particularly benefiting underserved populations across all healthcare settings. Among self-collection devices, vaginal brushes achieve sensitivity of 94.6% (95% CI: 92.4–96.8) for HPV detection, while novel approaches like the tampon show promising results (sensitivity 82.9–100%, specificity 91.6–96.8%) with high user acceptability. Implementation strategies vary by healthcare context, with high-income countries achieving success through integrated screening programmes and digital solutions, while LMICs demonstrate effective adaptation through community-based distribution (20–35% uptake) and innovative delivery methods. In resource-limited settings, self-sampling increases participation through enhanced patient comfort and cultural acceptability, while reducing costs by 32–48%. Progress toward WHO’s cervical cancer elimination goals require careful consideration of local healthcare infrastructure, cultural contexts and sustainable financing mechanisms. Future research priorities include optimising self-sampling technologies for sustainability and scalability, developing context-specific implementation strategies and validating artificial intelligence applications to enhance screening efficiency across diverse healthcare settings.

2 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SBStacey Bryan
Stacey Bryan
JLJen Lee
Jen Lee
RGRichard Gunu
Richard Gunu
AJAllison Jones
Allison Jones
AOAdeola Olaitan
Adeola Olaitan
SBShreerang A. Bhide
Shreerang A. Bhide
Background: High-risk HPV infection is responsible for >99% of cervix cancers (CC). In persistent infections that lead to cancer, the tumour breaches the basement membrane, releasing HPV-DNA into the bloodstream (cHPV-DNA). A next-generation sequencing assay (NGS) for detection of plasma HPV circulating DNA (cHPV-DNA) has demonstrated high sensitivity and specificity in patients with locally advanced cervix cancers. We hypothesised that cHPV-DNA is detectable in early invasive cervical cancers but not in pre-invasive lesions (CIN). Methods: Blood samples were collected from patients with CIN (n = 52) and FIGO stage 1A-1B CC (n = 12) prior to treatment and at follow-up. DNA extraction from plasma, followed by NGS, was used for the detection of cHPV-DNA. Results: None of the patients with pre-invasive lesions were positive for CHPV-DNA. In invasive tumours, plasma from one patient (10%) reached the threshold of positivity for cHPV-DNA in plasma. Conclusion: Low detection of cHPV-DNA in early CC may be explained by small tumour size, poorer access to lymphatics and circulation, and therefore little shedding of cHPV-DNA in plasma at detectable levels. The detection rate of cHPV-DNA in patients with early invasive cervix cancer using even the most sensitive of currently available technologies lacks adequate sensitivity for clinical utility.

23 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MGMichelle Gomes
Michelle Gomes
EPElena Provaggi
Elena Provaggi
APANDREA BARNABAS PEMBE
ANDREA BARNABAS PEMBE
AOAdeola Olaitan
Adeola Olaitan
AGAleksandra Gentry-Maharaj
Aleksandra Gentry-Maharaj
Cervical cancer causes 350,000 deaths annually, with 90% occurring in low and middle-income countries (LMICs), despite being largely preventable through vaccination and screening. This review examines innovative approaches to address screening coverage gaps worldwide, analysing both established programs in high-income countries and implementation strategies for LMICs. Self-sampling technologies demonstrate significant potential to increase screening participation by 1.5 to 2.5 times compared to traditional methods, particularly benefiting underserved populations across all healthcare settings. Vaginal brushes achieve the highest sensitivity (94.6%, 95% CI: 92.4-96.8) for HPV detection, while novel approaches like tampon sampling show promising acceptability and performance metrics. Implementation strategies vary by healthcare context, with high-income countries achieving success through integrated screening programs and digital solutions, while LMICs demonstrate effective adaptation through community-based distribution (20-35% uptake) and innovative delivery methods. In resource-limited settings, self-sampling increases participation through enhanced patient comfort and cultural acceptability, while reducing costs by 32-48%. Progress toward the WHO's cervical cancer elimination goals require careful consideration of local healthcare infrastructure, cultural contexts, and sustainable financing mechanisms. Future research priorities include optimising self-sampling technologies for sustainability and scalability, developing context-specific implementation strategies, and validating artificial intelligence applications to enhance screening efficiency across diverse healthcare settings.

6 August 2021
Verified
Book Chapter
Closed access
PDF file
AOAdeola Olaitan
Adeola Olaitan
MEMichael Chudi Ezeanochie
Michael Chudi Ezeanochie